Nektar reports estimated cash and investments of $741.7M as of April 1, 2026

NEKTAR THERAPEUTICS

Cash and marketable securities estimated at $741.7 million as of April 1, 2026.
Announcement is a preliminary estimate, not a comprehensive financial statement.
Amount based solely on information available as of April 20, 2026 filing date.
No other financial results or guidance provided in the release.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.